Search

Background and Purpose: Scedosporium apiospermum complex as a ubiquitous environmental mold is increasingly reported to cause an invasive fungal infection in immunosuppressive hosts. Herein, we present the case of an immunosuppressive 54-year-old man who developed S. apiospermum complex lung infection and pulmonary adenocarcinoma. Case report: The patient had some complaints of dyspnea and cough during a neutropenic episode. The computed tomography (CT) scan of the patient revealed pleural effusion. After culturing the pleural fluid sample, the fungus was identified by microscopic examination and ITS sequencing. In addition, antifungal susceptibility testing was performed using the M38-A2 microdilution method. The minimum inhibitory concentrations of amphotericin B, voriconazole, posaconazole, and caspofungin were obtained as > 64, 0.06, 0.06, and 0.03 μg/mL, respectively. Voriconazole (administered in two doses of 6 mg/kg and a maximum of 250 mg) was preferred for treatment. The patient received antifungal treatment for 2 months; however, he was lost to follow-up. Conclusion: Scedosporium apiospermum complex should be considered a cause of systemic fungal infections in neutropenic patients. Furthermore, the determination of the in vitro antifungal susceptibilities of clinical strains may contribute to the development of therapeutic approaches.

Objective: There is still no diagnosis method with high sensitivity and specificity for COVID-19. Patient complaints, real-time reverse transcription-polymerase chain reaction (RT-PCR), inflammatory markers, clinical prognosis, and the degree of involvement in the chest CT, if necessary are evaluated in an effort to make a diagnosis. Delays in diagnosis have led to a rapid spread of the disease. This study aims to evaluate the effectiveness of the inflammatory markers and to determine the follow-up process of the patients by assessing the impact of the treatments administered on RT-PCR test results. Material and methods: Files of 150 patients monitored in the wards with suspected COVID-19 are analyzed retrospectively. Patients were selected among those who underwent laboratory tests, RT-PCR testing and Thoracic CT within the first 24 hours of admission. Patients were divided into 5 groups based on the severity of involvement in Thoracic CT. Inflammatory markers were compared among the groups. Impact of the administered treatments on follow-up RT-PCR test results was evaluated. Results: Studied inflammatory markers were in normal ranges and similar across all CORADS groups. Only the C-Reactive Protein (CRP) and Ferritin levels were showing an increase in accordance with CORADS severity. Mean time to testing negative on RT-PCR was 10 days across all treatment groups. Times to testing negative among patients receiving other treatments were similar. Conclusion: Among the inflammatory markers, CRP and Ferritin values are correlated with CORADS severity. Administered COVID-19 treatments have similar impact on RT-PCR test results.